Ryvu Therapeutics Reports 2024 Half-Year Financial Results and Provides Corporate Update

The total operating revenues in H1 2024 amounted to USD 12.1 million and increased by USD 4.2 million compared to H1 2023. As of September, 5 2024, Ryvu’s cash position was USD 65.3 million. Together with other already secured funding sources, this cash position provides a runway through…